NanoEntek, Inc. engages in the research and development, production, and sale of life-science lab equipment, in vitro diagnostic medical devices, point of care diagnostic devices, and related consumables and solutions in Korea and internationally. It provides FREND system, a fluorescence immunoassay analyzer; BUDDI, a rapid diagnostic test analyzer; rapid diagnostic test items; ADAM-rWBC, a residual white blood cell counters; ADAMII/fluorescence stem cell counter; fluorescence cell counters and cell analyzers; brightfield cell counters; somatic cell counters; live-cell imaging system; and disposable hemocytometers. The company was founded in 1987 and is headquartered in Seoul, South Korea.
Metrics to compare | 039860 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship039860PeersSector | |
---|---|---|---|---|
P/E Ratio | 171.3x | −2.7x | −0.7x | |
PEG Ratio | 1.58 | −0.02 | 0.00 | |
Price/Book | 1.5x | 1.3x | 2.6x | |
Price / LTM Sales | 3.6x | 2.9x | 3.2x | |
Upside (Analyst Target) | - | 51.5% | 43.2% | |
Fair Value Upside | Unlock | 28.6% | 6.8% | Unlock |